NCT04588545 2026-02-09
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT01373710 2025-11-24
HIT
Institut Curie
Phase 1/2 Completed
NCT06462092 2025-09-29
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06462222 2025-09-29
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Guangzhou Medical University
Phase 1/2 Active not recruiting
NCT07177950 2025-09-17
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
Peking University Cancer Hospital & Institute
Phase 1/2 Not yet recruiting
NCT06762080 2025-05-20
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06809517 2025-05-20
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06809530 2025-05-18
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT05289908 2025-05-04
Intrathecal Pemetrexed for Leptomeningeal Metastasis
The First Hospital of Jilin University
Phase 1/2 Completed
NCT00924820 2020-12-31
A Pilot Study of Bevacizumab for Neoplastic Meningitis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03507244 2019-12-26
Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors
The First Hospital of Jilin University
Phase 1/2 Completed
NCT01596127 2018-05-24
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00002751 2013-06-20
Monoclonal Antibody Therapy in Treating Patients With Brain Metastases
Duke University
Phase 1/2 Completed